Regarding therapeutic application targeting the FAM83H-SCRIB pathway, the knock-down of FAM83H and/or SCRIB inhibited the growth of various human cancer cells, such as hepatocellular carcinoma [3], gastric carcinoma [7], ovarian carcinoma [24], and osteosarcoma [6]. This evidence concerns the gene SACK1H and hepatocellular carcinoma.